Resource Library
HISTOSELECT®: The number one solution for direct screening of large numbers of antibodies by immunohistochemistry (IHC).
Reach out to our experts and discover how we can help you advance your research
Resource Library
Since 1967, Cerba HealthCare Group has accompanied scientific and technological advances in diagnosis, prevention and precision medicine in order to better meet the expectations of health professionals and patients. This constant quest for improvement has led Cerba Research to create one of the world’ s largest and multinational commercial biorepository with the unique goal of contributing to the advancement of Science.
As a specialty and central laboratory for clinical trials covering 5 continents, our biospecimen provision is the starting point for your research to facilitate further downstream decisions inclusion: robust assay development and assay validation with quality samples.
Reach out to our experts and discover how we can help you advance your research
Resource Library
Resource Library
Cerba Research offers in-house in situ biomarkers expertise managed by our research scientists, with over 200 optimized IHC and IF protocols, from simplex to multiplex solutions, to suit the needs of any project. The scientific-driven R&D team can provide complete IHC assay development/optimization or assay transfer of clients’ methods and the subsequent fit-for-purpose validation.
Biomarkers can triple drug development success rates when used in clinical research. While scientific and technological advances have led to the discovery of more circulating biomarker candidates, the challenge lies in validating those biomarkers.
Cerba Research takes a personalized approach to biomarker assay development and validation to help clients improve their odds of success. This approach involves the experience of our leading scientists, and our five-continent laboratory network.
Our highly specialized custom assays, innovative anatomical pathology biomarker support, and biomarker strategies de-risk study conduct and generate the data you need to bring new therapies to light. From translational research to clinical through commercialization, Cerba actuates real-world data to help you reach patients and bring clarity to complex research.
Cerba Research provides flexible, tailored biomarker solutions through a network of labs across five continents. When you partner with us, you gain the operational and scientific expertise to advance targeted approaches and broad immune profiling. Together, we will develop biomarker strategies that help your trial succeed.
But which biomarkers can Cerba Research test on? Discover it here in this downloadable brochure.
Reach out to our experts and discover how we can help advance your research
Resource Library
Experience the fascinating world of histopathology through the eyes of our skilled scientists.
Immunohistochemistry (IHC) biomarkers are crucial in clinical development. These tissue biomarkers assist in diagnosis confirmation, patient selection, and mechanistic evaluation.
Our team of IHC experts offers personalized consultations, providing flexible and efficient solutions tailored to your specific needs. We are committed to delivering timely, cost-effective results to achieve your clinical and commercial objectives.
Why Choose Cerba Research For IHC Services?
Download our digital book to explore the art of histopathology and learn how Cerba Research can support your clinical research goals.
Reach out to our experts and see how we can help advance your clinical trial
Resource Library
The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.
In this webinar our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.
Speakers
Reach out to our experts to see how we can help advance your clinical trial
Resource Library
It is now clear that the therapeutic future lies in biomarkers through the development of immunotherapies and companion diagnostics. Among the techniques of biomarker analysis, there is Flowcytometry, which allows for precise analysis of liquid samples, but not only.
Validation test development for specific biomarkers is a prerequisite for a successful application in translational research, preclinical and clinical phases. The advantages and disadvantages of this technique, the samples, and the conditions of use: Cerba Research will open the doors of its worldwide laboratories for an hour. To answer all your questions about one of the leading techniques of analysis for the development of innovative treatments, our experts will share their knowledge and experience.
Nithianandan obtained his PhD in Immunology and started to work on HIV research. After more than 10 years of HIV research, he joined a biotech company to work on biomarker discovery for autoimmune diseases. His interest in Flow cytometry at the biotech company led him to join global CRO to work on assay development and validation in Flow cytometry for global clinical trials. He joined Cerba Research to continue to work on his passion for Flow cytometry in clinical trial and takes on new challenges to build the best Flow cytometry service to the clients.
He is working with exceptional scientific teams in the US and Belgium to bring on new assays for various therapeutic indications, including Immuno-oncology and autoimmune diseases.
A microbiologist by education, Ishita finished her studies at Gujarat University in India and moved on to start her career in the United States. She has more than 15 years of experience in the clinical and diagnostic research industry. Her expertise is in building a strong foundation of clinical operations and clinical research with a commitment to meeting client’s scientific needs to help advance medicine. Ishita has worked at CRO/Central Lab as well as at some of the leading clinical diagnostic labs in the region. Her scientific expertise includes infectious diseases and genetics, and gained extensive experience in microbiology, virology, and molecular biology. Ishita is a New York State-certified Medical Technologist and also a certified IRB (Institutional Review Board) professional. Her experience over the years has made her very strong in all aspects of clinical research and regulatory requirements. She has a passion for advancing science and making a difference in the future of healthcare.
Reach out to our experts to see how we can help advance your clinical trial
Resource Library
Biomarkers are at the heart of Immuno-Oncology. In this webinar, we will walk you through three case studies to highlight the importance of biomarkers, using different methodologies. Why do some patients respond better to I/O therapeutics than others? What is Flow Cytometry’s role in immunophenotyping? Where does Immunohistochemistry come in? What is the Tumor Mutation Burden, how does it impact I/O research?
Amanda Finan, Head of IHC R&D Cerba Research, Nithianandan Selliah, Global Head of Flow Cytometry Cerba Research, and Raouf Ben Abdelali, Head of the Hematology and Oncology Division, Cerba Laboratory will guide you through their respective fields of expertise and answer the above questions.
Reach out to our experts and discover how we can help you advance your clinical trial
Resource Library
The new Vitro Diagnostic Regulation legislation comes into force on May 26, 2022. Diagnostic device manufacturers are working hard to ensure design, manufacturing, and post-market surveillance and vigilance of their products comply with the new regulations. As the clock ticks, few manufacturers are fully prepared: according to a survey conducted by MedTech Summit and NSF in early 2021, only 15% of respondent organizations were fully prepared to meet the IVDR deadline.
One of the main reasons for the delay was COVID-19. Almost all (95%) of respondents said the pandemic had impacted their IVDR implementation. While the European Commission recently proposed to adapt the full IVDR mandatory application dates depending on the class of medical device, organizations that are not already working with a Notified Body on CE mark submission may have a tough few years ahead. Download our whitepaper to find out more from Cerba Research.
Reach out to our experts to discover how we can help you advance your clinical trial
Resource Library
While most people with COVID-19 recover within a few weeks, a notable percentage experience symptoms that last for 12 weeks or longer. With therapy development, we look into clinical diagnostics.
As scientists discover new variants, new questions become more relevant: How will variants impact vaccine efficacy? Who will need booster shots? Will we need new vaccines? Targeting a multifaceted disease such as COVID-19 requires a diverse team of infectious disease experts; it will also require a central lab and clinical diagnostics partner with the expertise and portfolio of testing to serve sponsors’ varied needs.
As the effort to develop more effective COVID-19 treatments and vaccines and protect the global public continues, therapy and vaccine developers must partner with central labs that offer a broad scope of services. A diverse portfolio of exploratory tools and tests is paramount when studying an unpredictable virus.
Find out more about Cerba’s research into COVID-19 by downloading our white paper.
Reach out to our experts and discover how we can help you advance your clinical trials
